These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6506000)

  • 21. [Chemical surveillance in the industrial environment].
    Conso F
    Rev Prat; 1987 Apr; 37(23):1321-5. PubMed ID: 3602879
    [No Abstract]   [Full Text] [Related]  

  • 22. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid].
    Lagier G; Vincens M; Castot A
    Therapie; 1983; 38(3):303-18. PubMed ID: 6612667
    [No Abstract]   [Full Text] [Related]  

  • 23. Critical reflection on the collection and evaluation of adverse drug reaction data.
    Venulet J
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
    [No Abstract]   [Full Text] [Related]  

  • 24. [Post-marketing surveillance of drugs: epidemiologic approach].
    Stanulović M; Jakovljević V; Sabo A
    Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
    [No Abstract]   [Full Text] [Related]  

  • 25. [A network of regional correspondents for studying undesirable effects].
    Haramburu F; Péré JC; Begaud B; Albin H
    Therapie; 1985; 40(5):321-4. PubMed ID: 4095688
    [No Abstract]   [Full Text] [Related]  

  • 26. The diagnosis of adverse medical events associated with drug treatment.
    Stephens MD
    Adverse Drug React Acute Poisoning Rev; 1987; 6(1):1-35. PubMed ID: 3303863
    [No Abstract]   [Full Text] [Related]  

  • 27. [How to assess the risk of drugs?].
    Roujeau JC
    Ann Dermatol Venereol; 1998 Oct; 125(10):673-5. PubMed ID: 9835953
    [No Abstract]   [Full Text] [Related]  

  • 28. [Microcomputerized data bank of nephrotoxic drugs at the Paris-Saint Antoine Regional Drug Monitoring Center].
    Hamel JD; Biour M; Cheymol G
    Therapie; 1986; 41(5):327-9. PubMed ID: 3810519
    [No Abstract]   [Full Text] [Related]  

  • 29. Post marketing surveillance. Traps for the unwary.
    Marley J; Mant A
    Aust Fam Physician; 1993 Jun; 22(6):1009-11, 1013. PubMed ID: 8338446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Responsibility of the pharmaceutical industry toward the first undesirable effects of new products].
    Juillet Y; de Cremiers F
    Therapie; 1988; 43(5):385-8. PubMed ID: 3227498
    [No Abstract]   [Full Text] [Related]  

  • 31. Revised ADR report permits internal review of drug experience.
    Jeffrey LP
    Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
    [No Abstract]   [Full Text] [Related]  

  • 32. Counseling regarding pregnancy--related drug exposures by family physicians in Ontario.
    Goodwin J; Rieder S; Rieder MJ; Matsui D
    Can J Clin Pharmacol; 2007; 14(1):e58-69. PubMed ID: 17314415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Critical analysis of the adverse effects reported to the Paris-Fernand Widal Drug Monitoring Center in a 2-month period].
    Castot A; Carlier P; Lagier G; Elmalem J; Vincens M; Efthymiou M
    Therapie; 1986; 41(5):375-7. PubMed ID: 3810528
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug-induced cancer.
    Prescrire Int; 2010 Feb; 19(105):21. PubMed ID: 20455337
    [No Abstract]   [Full Text] [Related]  

  • 35. Postmarketing management of drug use: toward rational public policy.
    Spitzer WO; Hutchinson T; Lane D
    CMAJ; 1987 May; 136(10):1022-4. PubMed ID: 3567760
    [No Abstract]   [Full Text] [Related]  

  • 36. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France].
    Bégaud B; Evreux JC; Jouglard J; Lagier G
    Therapie; 1985; 40(2):111-8. PubMed ID: 4002188
    [No Abstract]   [Full Text] [Related]  

  • 37. ["There are clear criteria for product surveillance studies"].
    Throm S
    MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777
    [No Abstract]   [Full Text] [Related]  

  • 38. [30 years' spontaneous recording systems of German physicians--results and experiences].
    Kimbel KH
    Verh Dtsch Ges Inn Med; 1989; 95():683-6. PubMed ID: 2603503
    [No Abstract]   [Full Text] [Related]  

  • 39. [Physician and pharmaceutical industry. II. Postmarketing surveillance].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1992 Jan; 136(1):36-41. PubMed ID: 1728761
    [No Abstract]   [Full Text] [Related]  

  • 40. [Drug safety. Notes about surveillance].
    Moreno Alvarez PJ; Madurga Sanz M
    Farm Hosp; 2004; 28(3):225-8. PubMed ID: 15222877
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.